In this article, we explore the 10 Best Multibagger Penny Stocks to Invest In.

Small-cap and penny stocks are often overlooked by Wall Street as they tend to be extremely volatile. However, not this time, as the overall equity market undergoes a correction fueled by concerns over premium valuations, geopolitical uncertainties, and inflationary pressures. While the S&P 500 has shed nearly 4% in market value year to date, the small-cap index, the Russell 2000, has held steady and is flat for the year.

The outperformance among small-cap companies comes as investors navigate the latest bout of geopolitical and market turmoil triggered by the Iran war. All the major indices, except the Russell 2000, have turned negative as the Middle East conflict raises the prospect of a recession amid higher energy prices and disruptions to global commerce.

According to Oppenheimer, small-cap companies are poised for a significant surge as spring gets underway. The stocks were off to a solid start for the year on hopes of easier monetary policy and a pivot away from large caps amid concerns over premium valuations.

“It usually is the smaller companies that take the beating first,” said Sam Stovall, chief investment strategist at CFRA Research. “Questions over a softening in economic growth, stagflation, or even a recession, are more apt to adversely affect small caps than large caps, thus placing them between a rock and a hard place.”

While the overall equity markets have pulled back significantly, the selloff has yet to spark a full-blown panic, according to Citigroup traders. Consequently, the pullback might have presented an ideal entry point for high-risk, high-reward investments such as penny stocks, given that the US economy remains robust.

“Small caps are a good place to be generally, and globally, in part because they’ve been overlooked for a long period of time,” said Dan Boston, head of the global small company team at Polar Capital America. “What we see going forward is small caps doing well vis-a-vis large caps.”

Our Methodology

To compile our list of the best multibagger penny stocks to buy right now, we used Finviz screener to scan for stocks trading for less than $5 a share (as of March 31). We focused on penny stocks with upside potential of more than 100%. We also considered institutional interest in each stock using hedge fund holdings data from Insider Monkey’s 13F database, as of Q4 2025. Finally, we ranked the stocks in ascending order based on their upside potential.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research shows we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).

Best Multibagger Penny Stocks to Invest In

10. Americas Gold and Silver Corporation (NYSEAMERICAN:USAS)

Share Price: $4.91

Stock Upside Potential: 134.48%

Number of Hedge Fund Holders: 19

Americas Gold and Silver Corporation (NYSEAMERICAN:USAS) is one of the best multibagger penny stocks to invest in. On March 30, Americas Gold and Silver Corporation (NYSEAMERICAN:USAS) delivered solid 2025 results and guidance. Silver production in the year was up 52% year over year due to operational improvements and efficiencies at the Galena Complex in Idaho.

The company achieved consolidated silver production of 2.65 million ounces, or approximately 3.4 million silver equivalent, and revenue in the year was up 18% to $118 million, driven by higher silver production and processing. Americas Gold and Silver realized a 39% increase in silver prices, offsetting 4.3% declines in lead and 0.8% in zinc.

However, Americas Gold and Silver Corporation plunged to a wider-than-expected adjusted loss of $35.2 million, or $0.13 a share, compared to an adjusted loss of $33.7 million, or $0.32 a share, in 2024. Adjusted EBITDA was a loss of $4.1 million, up from $1.5 million in 2024, due to increased operational spending as part of a strategic investment at Galena to enhance production.

Americas Gold and Silver Corporation (NYSEAMERICAN:USAS) is a North American precious metals mining company focused on exploring, operating, and developing high-grade silver, copper, and antimony projects. The company operates the Galena Complex in Idaho, USA, and the Cosalá Operations in Mexico, aiming to be a top-tier silver and antimony producer.

9. Recursion Pharmaceuticals Inc. (NASDAQ:RXRX)

Share Price: $3.06

Stock Upside Potential: 146.45%

Number of Hedge Fund Holders: 29

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the best multibagger penny stocks to invest in. On March 31, Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) and Citeline expanded their strategic partnership to further develop the artificial intelligence-enabled ClinTech Platform.

The expanded partnership also underscores the company’s commitment to building a more predictive and patient-centered biopharmaceutical ecosystem. It also follows the integration of Citeline’s SmartSolutions into the Recursion platform to provide data access during early development stages.

The expanded partnership paves the way for integrating Citeline’s real-world data and evidence capabilities into Recursion’s end-to-end platform. The integration will strengthen the platform’s foundation, enabling more precise trial design, improved site selection, and informed development decisions.

The addition of Citeline’s data and evidence capabilities to the company’s robust platform is also poised to support pipeline development. The ClinTech platform is already yielding results, including 30%-60% improvements in enrollment, affirming the importance of integration.

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is a clinical-stage “TechBio” company that uses artificial intelligence (AI), machine learning, automation, and high-throughput biology to enhance drug discovery and development.

8. Genius Sports Limited (NYSE:GENI)

Share Price: $4.54

Stock Upside Potential: 154.45%

Number of Hedge Fund Holders: 41

Genius Sports Ltd. (NYSE:GENI)is one of the best multibagger penny stocks to invest in. On March 27, Benchmark reiterated a Buy rating on Genius Sports Ltd. (NYSE:GENI) and a $10 price target. The positive stance comes on the heels of the company’s announcement of a major expansion of its Moment Engine platform.

The company has successfully integrated the solution across partners to collectively represent 90% of the advertising ecosystem. With the integration, the company has asserted its position as a reliable layer for sports advertising while connecting live sports data across the digital media ecosystem.

Genius Sports has tailored Moment Engine to act on fan attention and automatically trigger campaigns when live action is most compelling. It has already been deployed during key sporting events, including the Super Bowl, where brands successfully triggered campaigns in real time.

Some of the key adopters include Publicis, Magnite, OpenX, PubMatic, FreeWheel, and DIRECTV. According to Benchmark, Genius Sports is well-positioned to capitalize on this, given that its current integrations account for 90% of the digital advertising ecosystem.

Genius Sports Limited (NYSE:GENI) is a global leader in sports data, technology, and broadcasting, acting as the official partner to over 700 sports organizations, including the NFL, EPL, and NBA. It captures real-time statistics, power sportsbooks’ live betting, delivers AI-driven video analytics, and provides fan engagement tools to leagues and media companies.

7. Nuvation Bio Inc. (NYSE:NUVB)

Share Price: $4.51

Stock Upside Potential: 187.08%

Number of Hedge Fund Holders: 40

Nuvation Bio Inc. (NYSE:NUVB) is one of the best multibagger penny stocks to invest in. On March 27, analysts at H.C. Wainwright reiterated a Buy rating on Nuvation Bio Inc. (NYSE:NUVB) with a $17 price target. The bullish stance is in response to positive regulatory developments in Europe.

The European Medicines Agency has validated the company’s Marketing Authorization Application for the candidate treatment of advanced ROS1-positive non-small cell lung cancer. Consequently, the review of taletrectinib is expected to take 1 year. The research firm expects an uneventful approval process in the EU, based on the topline clinical trial data.

Nuvation Bio made the submission following positive pivotal Phase 2 TRUST-I and TRUST-II studies. Therefore, European Market authorization is to be supported by favorable feedback received at a permission meeting with the CHMP Rapporteur and Co-Rapporteur.

The company is on course to secure $30 million in milestone payments from partner Eisai on securing EU regulatory approval. The drug has already received full approval in the US from the Food and Drug Administration.

Nuvation Bio Inc. (NYSE:NUVB) is a commercial-stage global biopharmaceutical company, founded in 2018, focused on developing novel, targeted oncology therapies for difficult-to-treat cancers. In June 2025, they entered the commercial stage with the FDA approval of IBTROZI (taletrectinib), a next-generation inhibitor for ROS1-positive non-small cell lung cancer.

6. Precigen, Inc. (NASDAQ:PGEN)

Share Price: $3.93

Stock Upside Potential: 188.79%

Number of Hedge Fund Holders: 19

Precigen Inc. (NASDAQ:PGEN) is one of the best multibagger penny stocks to invest in. On March 26, analysts at Citizens reiterated a Market Outperform rating on Precigen Inc. (NASDAQ:PGEN) and hiked the price target to $9 from $8.

The price target hike underscores the research firm’s confidence in the company’s lead drug, PAPZIMEOS, as a frontline standard of care for recurrent respiratory papillomatosis. The drug received full FDA approval last year as the first immunotherapy for recurrent respiratory papillomatosis. Management has already indicated that they are on course to generate more than $18 million in PAPZIMEOS sales in the first quarter.

Citizen’s is confident sales will exceed guidance, given solid commercial metrics, including patient engagement and enrollment in hubs. Engaged patient profiles for papillomatosis are broad, including patients who have undergone many surgeries. The company remains well-positioned to capitalize on PAPZIMEOS edge as the first and only approved therapy for recurrent respiratory papillomatosis.

Precigen, Inc. (NASDAQ:PGEN) is a clinical-stage biopharmaceutical company focused on developing next-generation gene and cell therapies, specifically in immuno-oncology, autoimmune disorders, and infectious diseases.

Click to continue reading and see the 5 Best Multibagger Penny Stocks to Invest In.

Disclosure: None. Follow Insider Monkey on Google News.